CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
ipilimumab is a safe and effective treatment that causes few or mild side effects for locally advanced or metastatic, unresectable, refractory melanoma...
Phase 2
Commack, New York, United States and 9 other locations
This is an open label study evaluating lifileucel (LN-144) in patients with metastatic uveal melanoma....
Phase 1
West Harrison, New York, United States and 1 other location
participants with a type of skin cancer known as melanoma.The objective of this study is to see if the combination of fianlimab and cemipli...
Phase 2, Phase 3
Hartford, Connecticut, United States and 12 other locations
and safe treatment for people with advanced or metastatic mucosal melanoma that has not been treated before.The researchers think that a com...
Phase 2
Harrison, New York, United States and 1 other location
is to test the effects of the study drug, ensartinib, on the patient and the cancer. Ensartinib is a new, investigational type of treatment for melanoma...
Phase 2
Harrison, New York, United States and 3 other locations
and pharmacokinetic profiles of botensilimab as monotherapy and in combination with balstilimab in participants with advanced cutaneous melanoma...
Phase 2
New Haven, Connecticut, United States and 48 other locations
with the standard-of-care drug combination, nivolumab and relatlimab, is a safe and effective treatment for people with untreated, unresectable melanoma...
Phase 2
Hartford, Connecticut, United States and 8 other locations
study to evaluate the efficacy, safety, and tolerability of APX005M in combination with nivolumab and ipilimumab in patients with advanced melanoma...
Phase 1
New Haven, Connecticut, United States and 1 other location
This is a phase 2, Simon's 2-stage designed study with 2 cohorts of anti-PD-1/PD-L1 experienced patients with untreated brain metastases: 1) melanoma...
Phase 2
New Haven, Connecticut, United States
and pembrolizumab improves recurrence free survival (RFS) compared to pembrolizumab alone in participants with complete resection of cutaneous melanoma...
Phase 2
New Haven, Connecticut, United States and 20 other locations
Clinical trials
Research sites
Resources
Legal